eFFECTOR's lead lung cancer program falls through, stock crashes
2024-04-04
临床2期临床结果
eFFECTOR Therapeutics won’t be moving its lead candidate forward in frontline non-small cell lung cancer after its experimental drug failed a Phase 2 study.
In the KICKSTART trial, patients with PD-L1 ≥50% received Merck’s Keytruda with either tomivosertib or placebo as frontline treatment. Median progression-free survival in the tomivosertib arm was 13 weeks compared to 11.7 weeks with placebo, and the difference was not statistically significant, eFFECTOR reported on Thursday. Overall survival data were immature, but there was no trend favoring the experimental arm.
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。